Home > Insider Trading > Filing (0001012975-19-000489)

Filing Details

Accession Number:: 0001012975-19-000489
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-07-17 19:26:59
Reporting Period:: 2019-07-15

Accepted Time:: 2019-07-17 19:26:59
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1556263	Syros Pharmaceuticals Inc.	SYRS	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1219039	Keith Crandell	C/O Arch Venture Fund Vii 8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1219042	Robert Nelsen	C/O Arch Venture Fund Vii 8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1219043	Clinton Bybee	C/O Arch Venture Fund Vii 8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1402439	Arch Venture Fund Vii, L.p.	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1544443	Arch Venture Partners Vii, Llc	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1544444	Arch Venture Partners Vii, L.p.	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2019-07-15	2,700	$8.27	4,302,051	No	4	S	Direct
Common Stock	Disposition	2019-07-16	25,779	$7.81	4,276,572	No	4	S	Direct
Common Stock	Disposition	2019-07-17	34,521	$7.70	4,242,051	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.20 to $8.40, inclusive. The reporting person undertakes to provide to Syros Pharmaceuticals, Inc., any security holder of' Syros Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.75 to $7.825, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.5775 to $7.755, inclusive.
Beneficial ownership consists of 4,242,051 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.